Write your message
Volume 17, Issue 2 (May 2023)                   IJT 2023, 17(2): 79-86 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Khosraviani S, Emami A, Keshavarz Hedayati S, Keshavarz Shahbaz S, Aali E, Naderi Y. The Synergistic Glucose-lowering Effects of Metformin and Bavachinin on Type II Diabetic Rats. IJT 2023; 17 (2) :79-86
URL: http://ijt.arakmu.ac.ir/article-1-1169-en.html
1- Student Research Committee, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran.
2- Department of Pharmacology, School of Medicine, Qazvin University of Medical Science, Qazvin, Iran.
3- Cellular and Molecular Research Center, Research Institute for Prevention of Noncommunicable Disease, Qazvin University of Medical Sciences. Qazvin, Iran.
4- Cellular and Molecular Research Center, Research Institute for Prevention of Noncommunicable Disease, Qazvin University of Medical Sciences. Qazvin, Iran. , y.naderi@qums.ac.ir
Abstract:   (892 Views)
Background: Diabetes is one of the most prevalent endocrine disorders in humans, and its first-line medication is metformin. Peroxisome proliferator-activated receptor gamma (PPAR–γ) agonists are the adjuncts to metformin. Bavachinin is a PPAR pan-agonist with fewer side effects than metformin" into PPAR–γ agonists. In this study, the synergistic effects of metformin and Bavachinin were investigated on type II diabetic rats.
Methods: After four weeks of a high fat and glucose diet, type II diabetes was induced in 28 male Wistar rats, using injection of streptozotocin and nicotinamide. The animals were distributed into five groups of seven each: 1) Normal control (N), 2) Diabetic control (D), 3) Diabetic rats receiving metformin (DM), 4) Bavachinin (DB), and 5) Metformin plus Bavachinin (DMB). Oral glucose tolerance test (OGTT), fasting blood glucose (FBG), fasting insulin (FINS), homeostasis model assessment of β-cell function (HOMA-β), homeostasis model assessment of insulin resistance (HOMA-IR), and insulin sensitivity index (ISI) were obtained.
Results: The OGTT results in DM, DB, and DMB groups were significantly improved compared to that of D group. The FBG levels were significantly lower in DMB than in DB, DM, and D groups. The FINS levels of DMB were significantly less than those of DB, DM, and D groups. The HOMA-IR and HOMA-β were comparable between DMB and N groups. The ISI improved significantly in DMB compared to those in DM, DB, and D groups.
Conclusion: Bavachinin may be used combined with metformin for the treatment of type II diabetes at lower doses of metformin, thus having fewer side effects.
 
Full-Text [PDF 1122 kb]   (627 Downloads) |   |   Full-Text (HTML)  (178 Views)  
Type of Study: Research | Subject: General

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Iranian Journal of Toxicology

Designed & Developed by : Yektaweb